1 Buzdar AU,Hortobagyi G. Update on endocrine therapy forbreast cancer[J]. Clin Cancer Res，1998，4(3): 527-534.
2 王贤才主译.临床药物大典[M].第一版.青岛：青岛出版社，1990.1577. [3] Friedrich M, Mink D, Villrna Heinsen C， et al.Tamoxifen and proliferationof vaginal and cervical epithelium in postmenopausal woman with breast cancer[J]. EurJ Obstet Gynecol Reprod Biol，1998，80(2): 221-5.
3 Yasui M, Yayoi E, Nishi T， et al. A case of intra-arterial infusionchemotherapy for liver metastases of breast cancer[J]. Gan To Kagaku Ryoho. 1999，26(12):1936-6.
4 Hoshino K, Nakamura M, Ikeda H， et al.Effective chemo-endocrine combinationtherapy for obstructive-jaundice caused by multiple liver metastasis of recurrent breastcancer-a case report[J]. Gan To Kagaku Ryoho，1999，26(7): 983-7.
5 Harvey HA. Emerging role of aromatase inhibitors in the treatment of breastcancer[J]. Oncoligy Huntingt， 1998，12(3 Suppl 5):32-35.
6 Bajetta E, Zilembo N, Bichisao E. Aromatase inhibitors in the treatment ofpostmenopausal breast cancer[J]. Drugs Aging，1999，15(4):271-283.
7 Jonat W. LH-RH analogues-the rationale for adjuvant use in premenopausalwomen with early breast cancer[J]. Br J Cancer，1998，78 Suppl 4:5-8.
8 Robertson JF, Willsher PC, Winterbottom L， et al. Onapristone, aprogesterone receptor antagonist ,as first-line therapy in primary breast cancer[J].Eur J Cancer，1999，35(2):214-8.
9 Nomura y, Shirouzu M, Takayama T. Direct comparisons of adjuvant endocrinetherapy, chemotherapy, and chemoendocrine therapy for operable breast cancer patientsstratified by estrogen receptor and menopausal status[J].Breast Cancer Res Treat，1998，49(1):51-60.
10 Harvey HA. Emerging role of aromatase inhibitors in the treatment of breastcancer[J]. Oncology Huntingt，1998，12(3 Suppl 5):32-5.
同被引文献13
1Howell A.Faslodex(ICI 182780), an oestragen receptor downregulator[J].Eur J Cancer,2000,36(suppl 4):87～88.
2Bajetta E,Zilembo N,Bichlsao. Aromatase inhibitors in the treatment of postmenopausal breast cancer[J].Drugs Aging,1999,15(4):271～283.
3Kaufmann A. ZoladexTM(Goserelin)VS CMFas adjuvant therapy in pre/perimenopausal,node-positive,early breast cancer;preliminary efficacy results from the ZEBRA study[J].Breast,2001,10(suppl):s30.
7Fioretti F,Tavani A, Bosetti C,et al .Riskfactorsfor breast cancer innulliparous women[J].Br J Cancer,1999,79:1923～1923.
8Hamilton A,piccart M.Thethid-generation non-steroidalaromataseinhibitors:a review of their clinical benefits in the second-line hormonal treatment of advanced breast cancer[J].Anals pf Oncology,1999,10(4):377～384.
9Buzda AU, Hortobagyi GN.Recent advances in adjuvant therapy ofbreast cancer [J].Semin Oncol,1999,26(4 suppl 12):12～17.
10Bajetta E,Zilembo N,Bichisao E. Steroidal aromatase inhibitors in early patients [J].Crit Rer Oncol hematol,2000,33(2):137～142.
